NJ State Employees Deferred Compensation Plan’s Ligand Pharmaceuticals LGND Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,000	Closed	-$886K	–	224
2025 Q3	$886K	Hold	5,000	–	–	0.1%	202
2025 Q2	$568K	Hold	5,000	–	–	0.07%	260
2025 Q1	$526K	Hold	5,000	–	–	0.07%	261
2024 Q4	$536K	Hold	5,000	–	–	0.07%	281
2024 Q3	$500K	Hold	5,000	–	–	0.06%	289
2024 Q2	$421K	Hold	5,000	–	–	0.05%	314
2024 Q1	$366K	Hold	5,000	–	–	0.05%	342
2023 Q4	$357K	Hold	5,000	–	–	0.05%	350
2023 Q3	$300K	Hold	5,000	–	–	0.05%	354
2023 Q2	$361K	Hold	5,000	–	–	0.05%	335
2023 Q1	$368K	Hold	5,000	–	–	0.06%	339
2022 Q4	$334K	Sell	5,000 -3,015	-38%	-$196K	0.05%	347
2022 Q3	$431K	Hold	8,015	–	–	0.07%	272
2022 Q2	$446K	Hold	8,015	–	–	0.07%	276
2022 Q1	$562K	Hold	8,015	–	–	0.08%	270
2021 Q4	$772K	Hold	8,015	–	–	0.1%	215
2021 Q3	$697K	Hold	8,015	–	–	0.09%	226
2021 Q2	$656K	Hold	8,015	–	–	0.09%	245
2021 Q1	$762K	Hold	8,015	–	–	0.11%	202
2020 Q4	$497K	Hold	8,015	–	–	0.08%	254
2020 Q3	$477K	Hold	8,015	–	–	0.09%	228
2020 Q2	$559K	Hold	8,015	–	–	0.11%	192
2020 Q1	$364K	Hold	8,015	–	–	0.08%	242
2019 Q4	$521K	Hold	8,015	–	–	0.09%	258
2019 Q3	$498K	Hold	8,015	–	–	0.09%	246
2019 Q2	$571K	Hold	8,015	–	–	0.1%	205
2019 Q1	$629K	Buy	8,015 +3,206	+67%	+$243K	0.11%	180
2018 Q4	$407K	Buy	4,809 +1,924	+67%	+$205K	0.08%	281
2018 Q3	$494K	Sell	2,885 -321	-10%	-$48.4K	0.08%	321
2018 Q2	$414K	Sell	3,206 -6,412	-67%	-$715K	0.07%	365
2018 Q1	$991K	Hold	9,618	–	–	0.18%	142
2017 Q4	$822K	Buy	9,618 +3,206	+50%	+$278K	0.14%	200
2017 Q3	$545K	Sell	6,412 -4,274	-40%	-$338K	0.1%	302
2017 Q2	$809K	Hold	10,686	–	–	0.15%	211
2017 Q1	$706K	Hold	10,686	–	–	0.13%	233
2016 Q4	$677K	Hold	10,686	–	–	0.13%	239
2016 Q3	$680K	Hold	10,686	–	–	0.14%	229
2016 Q2	$795K	Hold	10,686	–	–	0.17%	203
2016 Q1	$782K	Hold	10,686	–	–	0.17%	208
2015 Q4	$723K	Hold	10,686	–	–	0.15%	224
2015 Q3	$571K	Hold	10,686	–	–	0.12%	258
2015 Q2	$673K	Hold	10,686	–	–	0.13%	251
2015 Q1	$514K	Hold	10,686	–	–	0.1%	287
2014 Q4	$355K	Hold	10,686	–	–	0.07%	315
2014 Q3	$313K	Hold	10,686	–	–	0.06%	328
2014 Q2	$415K	Hold	10,686	–	–	0.08%	312
2014 Q1	$448K	Hold	10,686	–	–	0.09%	309
2013 Q4	$351K	Hold	10,686	–	–	0.07%	327
2013 Q3	$289K	Hold	10,686	–	–	0.06%	345
2013 Q2	$249K	Buy	+10,686	New	+$192K	0.06%	351

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's LGND Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Ligand Pharmaceuticals (LGND) in Q4 2025, closing a stake of 5,000 shares — an estimated $886K sold.

NJ State Employees Deferred Compensation Plan first reported a position in LGND in Q2 2013 and held it in 50 quarters. The position peaked at $991K in Q1 2018. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Ligand Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 5,000 Ligand Pharmaceuticals shares in Q4 2025, an estimated $886K.
NJ State Employees Deferred Compensation Plan first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 50 quarters.
NJ State Employees Deferred Compensation Plan's Ligand Pharmaceuticals position peaked at $991K in Q1 2018.
349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.